Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimester

27 Sept 2010

Abstract excerpt

OBJECTIVE: To estimate the difference between levels of the two biochemical markers pregnancy-associated plasma protein-A (PAPP-A) and maternal serum free β-human chorionic gonadotropin (free β-hCG) in twin pregnancies relative to singleton pregnancies and establish an improved screening procedure for chromosomal abnormalities such as trisomy 21 in twin pregnancies. METHODS: 4843 unaffected and 47 trisomy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Assisted Reproductive Technology and Twin Pregnancy
Share to Prenatal Screening and Diagnostics
Share to Preterm Birth and Chorioamnionitis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20878678
DOI: 10.1002/uog.8845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A reassessment of biochemical marker distributions in trisomy 21‐affected and unaffected twin pregnancies in the first trimesterPMID 20878678Read ↗

Screening for trisomy 21 in twin pregnancies in the first trimester using free ?-hCG and PAPP-A, combined with fetal nuchal translucency thicknessSemantic proximity Read ↗

Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markersSemantic proximity Read ↗

First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsSemantic proximity Read ↗

Screening for trisomy 18 by maternal age, fetal nuchal translucency, free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐ASemantic proximity Read ↗

First‐trimester combined screening for trisomy 21 at 7–14 weeks' gestationSemantic proximity Read ↗

UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group.Semantic proximity Read ↗

The impact of fetal gender on first trimester nuchal translucency and maternal serum free β‐hCG and PAPP‐A MoM in normal and trisomy 21 pregnanciesSemantic proximity Read ↗

First trimester maternal serum placental growth factor in trisomy 21 pregnanciesSemantic proximity Read ↗

First‐trimester screening for fetal aneuploidy: biochemistry and nuchal translucencySemantic proximity Read ↗

First‐trimester screening for trisomy 21 combining biochemistry and ultrasound at individually optimal gestational ages. An interventional studySemantic proximity Read ↗

Maternal serum pregnancy‐associated plasma protein a and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.